Skip to main content
Log in

Atezolizumab/bevacizumab

Small bowel perforation: case report

Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Hagiwara S, et al. A case of HCC successfully treated with infliximab-steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy. Cancer Reports 5: No. 11, Nov 2022. Available from: URL: http://doi.org/10.1002/cnr2.1721

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Atezolizumab/bevacizumab. Reactions Weekly 1962, 82 (2023). https://doi.org/10.1007/s40278-023-41752-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-41752-0

Navigation